Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accounts Payables: 2016-2024

Historic Accounts Payables for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $58.3 million.

  • Tg Therapeutics' Accounts Payables rose 10.78% to $112.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.3 million, marking a year-over-year increase of 10.78%. This contributed to the annual value of $58.3 million for FY2024, which is 51.53% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Accounts Payables is $58.3 million, which was up 51.53% from $38.5 million recorded in FY2023.
  • Tg Therapeutics' Accounts Payables' 5-year high stood at $58.3 million during FY2024, with a 5-year trough of $37.0 million in FY2020.
  • For the 3-year period, Tg Therapeutics' Accounts Payables averaged around $46.3 million, with its median value being $42.0 million (2022).
  • As far as peak fluctuations go, Tg Therapeutics' Accounts Payables fell by 18.08% in 2022, and later surged by 51.53% in 2024.
  • Over the past 5 years, Tg Therapeutics' Accounts Payables (Yearly) stood at $37.0 million in 2020, then spiked by 38.58% to $51.3 million in 2021, then declined by 18.08% to $42.0 million in 2022, then declined by 8.44% to $38.5 million in 2023, then skyrocketed by 51.53% to $58.3 million in 2024.